Anti-CHD3 antibody [EPNCIR110A] - BSA and Azide free
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CHD3 antibody [EPNCIR110A] - BSA and Azide free (AB240942)
Immunohistochemical staining of paraffin-embedded Human ovary tissue using ab109195 at a dilution of 1/100.This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab109195)
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-CHD3 antibody [EPNCIR110A] - BSA and Azide free (AB240942)
Immunofluorescent staining of HeLa cells using ab109195 at a dilution of 1/100.This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab109195)
- Flow Cyt (Intra)
Lab
Flow Cytometry (Intracellular) - Anti-CHD3 antibody [EPNCIR110A] - BSA and Azide free (AB240942)
Intracellular Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling CHD3 with purified ab109195 at 1/230 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488) (ab150077) (1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) (ab172730) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab109195)
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CHD3 antibody [EPNCIR110A] - BSA and Azide free (AB240942)
Immunohistochemical staining of paraffin-embedded Human breast tissue using ab109195 at a dilution of 1/100.This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab109195)
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
- WB
Lab
Western blot - Anti-CHD3 antibody [EPNCIR110A] - BSA and Azide free (AB240942)
Lane 1 : Wild-type HAP1 cell lysate (20 μg)
Lane 2 : CHD3 knockout HAP1 cell lysate (20 μg)
Lane 3 : Raji cell lysate (20 μg)
Lane 4 : Y79 cell lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab109195 observed at 245 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab109195 was shown to specifically react with CHD3 when CHD3 knockout samples were used. Wild-type and CHD3 knockout samples were subjected to SDS-PAGE. ab109195 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW)preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 h at room temperature before imaging.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol and sodium azide (ab109195).
All lanes:
Western blot - Anti-CHD3 antibody [EPNCIR110A] (<a href='/en-us/products/primary-antibodies/chd3-antibody-epncir110a-ab109195'>ab109195</a>)
Predicted band size: 226 kDa
false
Related conjugates and formulations (10)
-
Anti-CHD3 antibody [EPNCIR110A]
-
660 APC
APC Anti-CHD3 antibody [EPNCIR110A]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-CHD3 antibody [EPNCIR110A]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-CHD3 antibody [EPNCIR110A]
-
603 Alexa Fluor® 568
Alexa Fluor® 568 Anti-CHD3 antibody [EPNCIR110A]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-CHD3 antibody [EPNCIR110A]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-CHD3 antibody [EPNCIR110A]
-
775 Alexa Fluor® 750
Alexa Fluor® 750 Anti-CHD3 antibody [EPNCIR110A]
-
HRP Anti-CHD3 antibody [EPNCIR110A]
-
578 PE
PE Anti-CHD3 antibody [EPNCIR110A]
Reactivity data
Product details
ab240942 is the carrier-free version of ab109195.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Collaborations
This antibody was developed as part of a collaboration between Epitomics, the National Cancer Institute's Center for Cancer Research and the lab of Gordon Hager.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CHD3 plays a significant role in modifying chromatin architecture and regulating the accessibility of the DNA to transcription factors. It functions as part of the NuRD (Nucleosome Remodeling and Deacetylase) complex which combines the features of ATP-dependent chromatin remodeling and histone deacetylase activity. CHD3 helps remodel nucleosomes and remove acetyl groups from histones which leads to chromatin condensation and transcriptional repression. Its activity influences genes involved in development differentiation and cell cycle control.
Pathways
CHD3's function integrates into pathways that control gene expression and DNA repair. It plays a role in the transcriptional regulation pathway working alongside proteins like HDAC1 and NuRD components. Additionally CHD3 participates in the DNA damage response cooperating with proteins such as CHD4 and RBBP4 to ensure genomic stability. These interactions and functions place CHD3 at a strategic position within cellular mechanisms maintaining transcription fidelity and genomic integrity.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Oncology letters 21:486 PubMed33968202
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com